CliffBio
biologic

Tecartus

Brexucabtagene Autoleucel

Loss of exclusivityJuly 2032projected — 12-year biologic exclusivity estimate
CompanyKite Pharma →View the full company profile on CliffBio

Drug detail

Brand nameTecartus
Active ingredientBrexucabtagene Autoleucel
Strength2×10^6 CAR-positive viable T cells per kg body weight
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJuly 2020
Marketing statusRx

More from Kite Pharma

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Tecartus patent cliff — loss of exclusivity July 2032 | CliffBio